Thomas W. Rice
Research Subjects
Research Interests
Thomas W. Rice has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
D. J. Adelstein
8 shared publicationsL. A. Rybicki
7 shared publicationsJ. P. Saxton
6 shared publicationsG. M. Videtic
5 shared publicationsS. C. Murthy
5 shared publicationsC. P. Rodriguez
4 shared publications
Latest Publications
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 4046
Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
4046 Background: HER2 is overexpressed in 21% of gastric and 33% of GEJ ACA, and pts with advanced HER2pos disease survive longer after chemotherapy and trastuzumab than after chemotherapy alone. This retrospective analysis was undertaken to better define the clinicopathologic features and treatment outcomes in pts with HER2pos ACA of the E and GEJ. Methods: Between 11/99 and 7/06, 156 pts with T3 or N1 or M1a ACA of the E or GEJ were entered on one of two Cleveland Clinic trials. Induction chemoradiation, with 96 hour infusions of cisplatin (20 mg/m2/d) and fluorouracil (1,000 mg/m2/d) beginning on day 1 of radiation (30 Gy at 1.5 Gy bid), was followed by surgery and identical post-operative chemoradiation. 76 pts also received 2 years of oral gefitinib. Pathology was tested for HER2 by immunohistochemistry using PATHWAY anti-HER-2/neu 4B5 Rabbit Monoclonal Primary Antibody (Ventana, Tucson AZ) and in situ hybridization with the INFORM HER2 Dual ISH DNA Probe Cocktail assay (Ventana, Tucson AZ). Baseline characteristics and outcomes after treatment of the HER2pos and negative (neg) pts were compared. Results: Of the 156 pts, 136 pts had either initial biopsy or resection specimen available. HER2 was deemed pos if either was pos. Discordance between biopsy and resection was found in only 6/65 pts (9%). 32 pts (24%) were HER2pos; 27% of 82 pts with GEJ, and 19% of 54 pts with E tumors (p=0.31). There was no statistical difference between HER2pos and neg pts in age, gender, race, stage, or pathological response. The only difference was that HER2neg tumors were more likely poorly differentiated (p<0.001). Locoregional control, distant metastatic control, freedom from recurrence and overall survival were statistically the same in both the entire cohort, and in the gefitinib-treated subset. Conclusions: Except for tumor differentiation, HER2pos and neg pts with ACA of the E and GEJ do not differ in clinicopathologic characteristics and treatment outcomes. Given the demonstrated benefit of trastuzumab in HER2pos gastric cancer and the similar incidence of HER2 overexpression in the E and GEJ, further evaluation of HER2 directed therapy in this disease seems indicated.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 4046
Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
4046 Background: HER2 is overexpressed in 21% of gastric and 33% of GEJ ACA, and pts with advanced HER2pos disease survive longer after chemotherapy and trastuzumab than after chemotherapy alone. This retrospective analysis was undertaken to better define the clinicopathologic features and treatment outcomes in pts with HER2pos ACA of the E and GEJ. Methods: Between 11/99 and 7/06, 156 pts with T3 or N1 or M1a ACA of the E or GEJ were entered on one of two Cleveland Clinic trials. Induction chemoradiation, with 96 hour infusions of cisplatin (20 mg/m2/d) and fluorouracil (1,000 mg/m2/d) beginning on day 1 of radiation (30 Gy at 1.5 Gy bid), was followed by surgery and identical post-operative chemoradiation. 76 pts also received 2 years of oral gefitinib. Pathology was tested for HER2 by immunohistochemistry using PATHWAY anti-HER-2/neu 4B5 Rabbit Monoclonal Primary Antibody (Ventana, Tucson AZ) and in situ hybridization with the INFORM HER2 Dual ISH DNA Probe Cocktail assay (Ventana, Tucson AZ). Baseline characteristics and outcomes after treatment of the HER2pos and negative (neg) pts were compared. Results: Of the 156 pts, 136 pts had either initial biopsy or resection specimen available. HER2 was deemed pos if either was pos. Discordance between biopsy and resection was found in only 6/65 pts (9%). 32 pts (24%) were HER2pos; 27% of 82 pts with GEJ, and 19% of 54 pts with E tumors (p=0.31). There was no statistical difference between HER2pos and neg pts in age, gender, race, stage, or pathological response. The only difference was that HER2neg tumors were more likely poorly differentiated (p<0.001). Locoregional control, distant metastatic control, freedom from recurrence and overall survival were statistically the same in both the entire cohort, and in the gefitinib-treated subset. Conclusions: Except for tumor differentiation, HER2pos and neg pts with ACA of the E and GEJ do not differ in clinicopathologic characteristics and treatment outcomes. Given the demonstrated benefit of trastuzumab in HER2pos gastric cancer and the similar incidence of HER2 overexpression in the E and GEJ, further evaluation of HER2 directed therapy in this disease seems indicated.
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 71
Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
71 Background: HER2 is overexpressed in 21% of gastric and 33% of GEJ ACA, and pts with advanced HER2pos disease survive longer after chemotherapy and trastuzumab than after chemotherapy alone. This retrospective analysis was undertaken to better define the clinicopathologic features and treatment outcomes in pts with HER2pos ACA of the E and GEJ. Methods: Between 11/99 and 7/06, 156 pts with T3 or N1 or M1a ACA of the E or GEJ were entered on one of two Cleveland Clinic trials. Induction chemoradiation, with 96 hour infusions of cisplatin (20 mg/m2/d) and fluorouracil (1,000 mg/m2/d) beginning on day 1 of radiation (30 Gy at 1.5 Gy bid), was followed by surgery and identical post-operative chemoradiation. 76 pts also received 2 years of oral gefitinib. Pathology was tested for HER2 by immunohistochemistry using PATHWAY anti-HER-2/neu 4B5 rabbit monoclonal primary antibody (Ventana, Tucson AZ) and in situ hybridization with the inform HER2 dual ISH DNA probe cocktail assay (Ventana, Tucson AZ). Baseline characteristics and outcomes after treatment of the HER2pos and negative (neg) pts were compared. Results: Of the 156 pts, 136 pts had either initial biopsy or resection specimen available. HER2 was deemed pos if either was pos. Discordance between biopsy and resection was found in only 6/65 pts (9%). 32 pts (24%) were HER2pos; 27% of 82 pts with GEJ, and 19% of 54 pts with E tumors (p=0.31). There was no statistical difference between HER2pos and neg pts in age, gender, race, stage, or pathological response. The only difference was that HER2neg tumors were more likely poorly differentiated (p<0.001). Locoregional control, distant metastatic control, freedom from recurrence and overall survival were statistically the same in both the entire cohort, and in the gefitinib-treated subset. Conclusions: Except for tumor differentiation, HER2pos and neg pts with ACA of the E and GEJ do not differ in clinicopathologic characteristics and treatment outcomes. Given the demonstrated benefit of trastuzumab in HER2pos gastric cancer and the similar incidence of HER2 overexpression in the E and GEJ, further evaluation of HER2 directed therapy in this disease seems indicated. No significant financial relationships to disclose.
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 71
Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
71 Background: HER2 is overexpressed in 21% of gastric and 33% of GEJ ACA, and pts with advanced HER2pos disease survive longer after chemotherapy and trastuzumab than after chemotherapy alone. This retrospective analysis was undertaken to better define the clinicopathologic features and treatment outcomes in pts with HER2pos ACA of the E and GEJ. Methods: Between 11/99 and 7/06, 156 pts with T3 or N1 or M1a ACA of the E or GEJ were entered on one of two Cleveland Clinic trials. Induction chemoradiation, with 96 hour infusions of cisplatin (20 mg/m2/d) and fluorouracil (1,000 mg/m2/d) beginning on day 1 of radiation (30 Gy at 1.5 Gy bid), was followed by surgery and identical post-operative chemoradiation. 76 pts also received 2 years of oral gefitinib. Pathology was tested for HER2 by immunohistochemistry using PATHWAY anti-HER-2/neu 4B5 rabbit monoclonal primary antibody (Ventana, Tucson AZ) and in situ hybridization with the inform HER2 dual ISH DNA probe cocktail assay (Ventana, Tucson AZ). Baseline characteristics and outcomes after treatment of the HER2pos and negative (neg) pts were compared. Results: Of the 156 pts, 136 pts had either initial biopsy or resection specimen available. HER2 was deemed pos if either was pos. Discordance between biopsy and resection was found in only 6/65 pts (9%). 32 pts (24%) were HER2pos; 27% of 82 pts with GEJ, and 19% of 54 pts with E tumors (p=0.31). There was no statistical difference between HER2pos and neg pts in age, gender, race, stage, or pathological response. The only difference was that HER2neg tumors were more likely poorly differentiated (p<0.001). Locoregional control, distant metastatic control, freedom from recurrence and overall survival were statistically the same in both the entire cohort, and in the gefitinib-treated subset. Conclusions: Except for tumor differentiation, HER2pos and neg pts with ACA of the E and GEJ do not differ in clinicopathologic characteristics and treatment outcomes. Given the demonstrated benefit of trastuzumab in HER2pos gastric cancer and the similar incidence of HER2 overexpression in the E and GEJ, further evaluation of HER2 directed therapy in this disease seems indicated. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 4547
A phase II trial of perioperative concurrent chemoradiotherapy (CCRT) and gefitinib (G) in locally advanced esophagus (E) and gastroesophageal junction (GEJ) cancer
4547 Background: Since 1999, Cleveland Clinic protocols for locally advanced E or GEJ cancer have used peri-operative CCRT. Despite high locoregional control (LRC) rates, distant metastatic control (DMC) and overall survival (OS) are suboptimal. This phase II study added G to our CCRT regimen in an effort to improve these outcomes. Methods: Eligibility required a diagnosis of E or GEJ squamous cell or adenocarcinoma (ACA), with an esophageal ultrasound stage of at least T3, N1, or M1a. Four-day (d) continuous IV infusions of cisplatin (20mg/m2/d), and fluorouracil (1,000 mg/m2/d) began on d1 of pre-operative radiation (30Gy at 1.5Gy bid). Surgery followed in 4–6 weeks (wks), followed by identical CCRT given 6–10 wks postoperatively. G (250 mg/d) was also started on d1 and given for 4 wks. It was restarted with the postoperative CCRT and given for 2 years. Targeted accrual was 80 patients (pts) with primary endpoints of OS and DMC. Results were retrospectively compared to 93 pts treated with an identical regimen without G. Results: Between 4/03 and 7/06, 80 pts were enrolled. Pt and tumor characteristics were similar to the non-G cohort. Median age was 58 (range 33–75) years; 73 pts (91%) were male and 75 (94%) Caucasian. Tumor began in distal E in 28 pts (35%) and GEJ in 46 (57%), and was an ACA in 75 (94%). Clinical staging was T3N0 in 15 pts (19%), T2–3N1 in 41 (51%) and T4 or M1a in 24 (30%). Induction toxicity was similar in G v. non-G pts except for grade 3–4 esophagitis in 3% v. 14% (p=0.007), neutropenia 1 rash in 42 pts (53%), and grade >1 diarrhea in 44 (55%). Resection was accomplished in 73 pts (91%) and post-operative CCRT completed in 60 (75%). With a median follow up of 33 (range 11–54) months, 3-year Kaplan-Meier estimates (G v. non-G pts) include: OS (40% v. 28%, p=0.07), DMC (46% v. 33%, P=0.20), and LRC (82% v. 77%, p=0.28). Only 50% of pts are projected to complete 2 years of maintenance G. Conclusions: Although toxicity was not increased by adding G to peri-operative CCRT, maintenance G was difficult. The suggestion of a survival advantage in this retrospective comparison merits additional investigation. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 4547
A phase II trial of perioperative concurrent chemoradiotherapy (CCRT) and gefitinib (G) in locally advanced esophagus (E) and gastroesophageal junction (GEJ) cancer
4547 Background: Since 1999, Cleveland Clinic protocols for locally advanced E or GEJ cancer have used peri-operative CCRT. Despite high locoregional control (LRC) rates, distant metastatic control (DMC) and overall survival (OS) are suboptimal. This phase II study added G to our CCRT regimen in an effort to improve these outcomes. Methods: Eligibility required a diagnosis of E or GEJ squamous cell or adenocarcinoma (ACA), with an esophageal ultrasound stage of at least T3, N1, or M1a. Four-day (d) continuous IV infusions of cisplatin (20mg/m2/d), and fluorouracil (1,000 mg/m2/d) began on d1 of pre-operative radiation (30Gy at 1.5Gy bid). Surgery followed in 4–6 weeks (wks), followed by identical CCRT given 6–10 wks postoperatively. G (250 mg/d) was also started on d1 and given for 4 wks. It was restarted with the postoperative CCRT and given for 2 years. Targeted accrual was 80 patients (pts) with primary endpoints of OS and DMC. Results were retrospectively compared to 93 pts treated with an identical regimen without G. Results: Between 4/03 and 7/06, 80 pts were enrolled. Pt and tumor characteristics were similar to the non-G cohort. Median age was 58 (range 33–75) years; 73 pts (91%) were male and 75 (94%) Caucasian. Tumor began in distal E in 28 pts (35%) and GEJ in 46 (57%), and was an ACA in 75 (94%). Clinical staging was T3N0 in 15 pts (19%), T2–3N1 in 41 (51%) and T4 or M1a in 24 (30%). Induction toxicity was similar in G v. non-G pts except for grade 3–4 esophagitis in 3% v. 14% (p=0.007), neutropenia 1 rash in 42 pts (53%), and grade >1 diarrhea in 44 (55%). Resection was accomplished in 73 pts (91%) and post-operative CCRT completed in 60 (75%). With a median follow up of 33 (range 11–54) months, 3-year Kaplan-Meier estimates (G v. non-G pts) include: OS (40% v. 28%, p=0.07), DMC (46% v. 33%, P=0.20), and LRC (82% v. 77%, p=0.28). Only 50% of pts are projected to complete 2 years of maintenance G. Conclusions: Although toxicity was not increased by adding G to peri-operative CCRT, maintenance G was difficult. The suggestion of a survival advantage in this retrospective comparison merits additional investigation. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 15519
Phase II trial of postoperative concurrent chemoradiotherapy (CCRT) for poor-prognosis cancer of the esophagus and gastroesophageal junction (GEJ)
15519 Background: CCRT is effective pre-operative and definitive treatment for patients (pts) with esophageal or GEJ cancer. This phase II trial was conducted to assess the benefit of post-operative CCRT in poor-prognosis pts after primary surgical resection. Methods: Resected pts with a pathologic stage of T3, N1 or M1a have a poor prognosis after surgery alone and were eligible for this trial. CCRT was begun between 6–10 weeks after surgery and consisted of radiotherapy (1.8 Gy/day (d) to a dose of 50.4–54 Gy), concurrent with two cycles of fluorouracil (1000 mg/m2/d) and cisplatin, (20 mg/m2/d); both given as 4-d continuous intravenous infusions during weeks 1 and 4 of the radiation. Primary end points were overall survival (OS) and freedom from recurrence (FFR). Results: Between 1994 and 2005, 50 pts were enrolled. The median age was 59 (range 33–76) years; 43 pts (86%) were male, and 48 (96%) were Caucasian. Histology was adenocarcinoma (ACA) in 43 pts (86%), and squamous cell carcinoma (SCC) in 7 (14%); and tumor originated in mid-esophagus in 4 (8%), distal esophagus 10 (20%) and GEJ in 36 (72%). The surgical procedure was a transthoracic esophagogastrectomy in 37 pts (74%), total gastrectomy in 8 (16%) and transhiatal esophagectomy in 5 (10%). Pathologic stage was T3N0M0 in 7 pts (14%), T1–4N1M0 in 40 (80%) and M1a in 3 (6%); 9 pts (18%) had positive margins. Postoperative CCRT was well tolerated with grade 3–4 nausea/vomiting in 4 pts (8%), mucositis/dysphagia in 6 (12%), and neutropenia < 1000/mm3 in 16 (32%) requiring hospitalization for fever in 4 (8%). There were no toxic deaths. With a median follow up of 63 (range 24–109) months, the Kaplan-Meier 5-year projected OS is 41%, FFR 42%, locoregional control 85% and distant metastatic disease control 47%. FFR was better in pts with SCC vs. ACA (86% vs. 34%, P=0.038). When comparing pts with T3N0, N1M0, and M1a disease, both OS (67% vs. 40% vs. 0%, P= 0.007) and FFR (80% vs. 35% vs. 0%, P=0.027), were better in pts with earlier pathologic stage. Conclusions: This schedule of postoperative CCRT is well tolerated in patients with poor-prognosis esophageal and GEJ cancer after surgery. Outcomes are better than historical results after surgery alone and justify further investigation of this approach. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 15519
Phase II trial of postoperative concurrent chemoradiotherapy (CCRT) for poor-prognosis cancer of the esophagus and gastroesophageal junction (GEJ)
15519 Background: CCRT is effective pre-operative and definitive treatment for patients (pts) with esophageal or GEJ cancer. This phase II trial was conducted to assess the benefit of post-operative CCRT in poor-prognosis pts after primary surgical resection. Methods: Resected pts with a pathologic stage of T3, N1 or M1a have a poor prognosis after surgery alone and were eligible for this trial. CCRT was begun between 6–10 weeks after surgery and consisted of radiotherapy (1.8 Gy/day (d) to a dose of 50.4–54 Gy), concurrent with two cycles of fluorouracil (1000 mg/m2/d) and cisplatin, (20 mg/m2/d); both given as 4-d continuous intravenous infusions during weeks 1 and 4 of the radiation. Primary end points were overall survival (OS) and freedom from recurrence (FFR). Results: Between 1994 and 2005, 50 pts were enrolled. The median age was 59 (range 33–76) years; 43 pts (86%) were male, and 48 (96%) were Caucasian. Histology was adenocarcinoma (ACA) in 43 pts (86%), and squamous cell carcinoma (SCC) in 7 (14%); and tumor originated in mid-esophagus in 4 (8%), distal esophagus 10 (20%) and GEJ in 36 (72%). The surgical procedure was a transthoracic esophagogastrectomy in 37 pts (74%), total gastrectomy in 8 (16%) and transhiatal esophagectomy in 5 (10%). Pathologic stage was T3N0M0 in 7 pts (14%), T1–4N1M0 in 40 (80%) and M1a in 3 (6%); 9 pts (18%) had positive margins. Postoperative CCRT was well tolerated with grade 3–4 nausea/vomiting in 4 pts (8%), mucositis/dysphagia in 6 (12%), and neutropenia < 1000/mm3 in 16 (32%) requiring hospitalization for fever in 4 (8%). There were no toxic deaths. With a median follow up of 63 (range 24–109) months, the Kaplan-Meier 5-year projected OS is 41%, FFR 42%, locoregional control 85% and distant metastatic disease control 47%. FFR was better in pts with SCC vs. ACA (86% vs. 34%, P=0.038). When comparing pts with T3N0, N1M0, and M1a disease, both OS (67% vs. 40% vs. 0%, P= 0.007) and FFR (80% vs. 35% vs. 0%, P=0.027), were better in pts with earlier pathologic stage. Conclusions: This schedule of postoperative CCRT is well tolerated in patients with poor-prognosis esophageal and GEJ cancer after surgery. Outcomes are better than historical results after surgery alone and justify further investigation of this approach. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 4047
Multimodality therapy (MMT) for locoregionally (LR) advanced cancer of the esophagus and gastroesophageal junction (E/GEJ): The impact of clinical heterogeneity
4047 Background: MMT programs for LR advanced cancer of the E/GEJ are usually protracted, with results that are often difficult to interpret because of nonuniformity of the population studied. We report mature results from a phase II trial of accelerated MMT with a focus on the impact of this clinical heterogeneity. Methods: Eligibility required a diagnosis of E/GEJ cancer, and an esophageal ultrasound (EUS) stage of at least T3 or N1 or M1a (M1b excluded). Patients (pts) were given a 12 day induction of radiation (1.5 Gy b.i.d. to a dose of 30 Gy), concurrent with 4 day continuous intravenous infusions of cisplatin (20mg/m2/day) and 5-fluorouracil (1000mg/m2/day) beginning on day 1. Surgery followed in 4–6 weeks, followed 6–10 weeks later by a second identical 12-day course of chemoradiotherapy (CRT). Results: From 10/99–3/03, 93 pts were enrolled; 96% were white, 86% male, and 83% had adenocarcinoma (ACA). EUS stage was T3N0M0 in 31%; T2–3N1M0 in 49%; and T4 or M1a in 19%. Induction CRT was well tolerated with no induction death, and grade 3–4 mucositis/dysphagia in 14%. Neutropenia < 1000/mm3 occurred in 38% requiring hospitalization for fever in 17%. Resection was possible in 83 pts (89%) with 3 (3%) peri-operative deaths. Post-operative CRT was possible in 65 pts and was similarly tolerated. With a median follow-up of 35 (range 20–59) months, the 3-year projected overall survival (OS) is 26%, freedom from recurrence (FFR) is 30%, and distant metastatic control (DMC) is 30%. Locoregional control in the 83 resected pts is 89%. The 3 year FFR was significantly worse for pts with ACA vs. squamous cancer (21% vs. 72%, P=.02), for the GEJ ACA pts vs. pts with ACA elsewhere (13% vs. 34%, P=.07), for EUS stage T4 or M1a vs. T3 or N1 (0% vs. 34%, P=.012), and for pathologically staged T4 or M1 vs. N1 vs. N0 disease (0% vs. 19% vs. 54%, P<.001). Similar observations were made for OS and DMC. Conclusions: This accelerated MMT is safe and feasible. Tumor location, histology, clinical stage and post-treatment pathologic stage impact significantly on results making comparisons of non-randomized experiences problematic. Distant metastases remain the major challenge in this disease. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 4047
Multimodality therapy (MMT) for locoregionally (LR) advanced cancer of the esophagus and gastroesophageal junction (E/GEJ): The impact of clinical heterogeneity
4047 Background: MMT programs for LR advanced cancer of the E/GEJ are usually protracted, with results that are often difficult to interpret because of nonuniformity of the population studied. We report mature results from a phase II trial of accelerated MMT with a focus on the impact of this clinical heterogeneity. Methods: Eligibility required a diagnosis of E/GEJ cancer, and an esophageal ultrasound (EUS) stage of at least T3 or N1 or M1a (M1b excluded). Patients (pts) were given a 12 day induction of radiation (1.5 Gy b.i.d. to a dose of 30 Gy), concurrent with 4 day continuous intravenous infusions of cisplatin (20mg/m2/day) and 5-fluorouracil (1000mg/m2/day) beginning on day 1. Surgery followed in 4–6 weeks, followed 6–10 weeks later by a second identical 12-day course of chemoradiotherapy (CRT). Results: From 10/99–3/03, 93 pts were enrolled; 96% were white, 86% male, and 83% had adenocarcinoma (ACA). EUS stage was T3N0M0 in 31%; T2–3N1M0 in 49%; and T4 or M1a in 19%. Induction CRT was well tolerated with no induction death, and grade 3–4 mucositis/dysphagia in 14%. Neutropenia < 1000/mm3 occurred in 38% requiring hospitalization for fever in 17%. Resection was possible in 83 pts (89%) with 3 (3%) peri-operative deaths. Post-operative CRT was possible in 65 pts and was similarly tolerated. With a median follow-up of 35 (range 20–59) months, the 3-year projected overall survival (OS) is 26%, freedom from recurrence (FFR) is 30%, and distant metastatic control (DMC) is 30%. Locoregional control in the 83 resected pts is 89%. The 3 year FFR was significantly worse for pts with ACA vs. squamous cancer (21% vs. 72%, P=.02), for the GEJ ACA pts vs. pts with ACA elsewhere (13% vs. 34%, P=.07), for EUS stage T4 or M1a vs. T3 or N1 (0% vs. 34%, P=.012), and for pathologically staged T4 or M1 vs. N1 vs. N0 disease (0% vs. 19% vs. 54%, P<.001). Similar observations were made for OS and DMC. Conclusions: This accelerated MMT is safe and feasible. Tumor location, histology, clinical stage and post-treatment pathologic stage impact significantly on results making comparisons of non-randomized experiences problematic. Distant metastases remain the major challenge in this disease. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 7168
Long-term follow-up after chemoradiotherapy (CRT) and surgery in patients (pts) with stage III non-small cell lung cancer (NSCLC): Is bulky mediastinal nodal disease of prognostic importance
7168 Background: Bulky mediastinal nodal involvement at presentation has been considered a poor prognostic factor in pts with stage III NSCLC. We present long-term follow-up from a phase II trial of accelerated fractionation radiation (AFR), concurrent chemotherapy and surgery, to address this issue. Methods: Between 10/94 and 9/00, 105 pts with surgically proven stage IIIA (N=78) or IIIB (N=27) NSCLC underwent induction treatment consisting of a 96-hour continuous cisplatin infusion (20 mg/m2/day) and a 24-hour infusion of paclitaxel (175 mg/m2) concurrent with AFR (1.5 Gy bid) to a dose of 30 Gy. Surgery was scheduled 4 weeks later, with a second identical course of CRT given 4–6 weeks post-operatively to a total dose of 60–63 Gy. Results: With a median follow-up of 59 (range 35–102) months, the projected Kaplan-Meier (KM) 5-year overall survival is 29%. KM 5-year locoregional and distant control are 85% and 39% respectively. KM 5-year survival was better in clinical stage IIIA vs. IIIB pts (33% vs. 19%, P=0.03); clinical responders to induction vs. non responders (36% vs. 17%, P=0.004); and pathologic responders vs. non-responders (45% vs. 11%, P < 0.001). Pathologic stage after surgery also predicted 5-year survival (stage 0-II: 55%; IIIA: 23%; IIIB - IV: 4%; P < 0.001). Pre-treatment mediastinoscopy identified 20 pts with only microscopic intra-nodal involvement in one or more ipsilateral nodes, and 61 pts with gross macroscopic, but ipsilateral, nodal disease. These two groups did not differ in median or 5-year KM survival (27 vs. 29 months, 45% vs. 27%, P= 0.45). The extent of ipsilateral nodal involvement contributed no prognostic information about survival in a Cox multivariable analysis. Conclusions: Clinical stage IIIA disease, clinical and pathologic response to induction, and a lower pathologic stage are important predictors for survival after this CRT protocol for pts with stage III NSCLC. Bulky ipsilateral mediastinal nodal involvement at diagnosis is of no prognostic importance for survival in these pts and should not be a consideration in treatment planning. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 7168
Long-term follow-up after chemoradiotherapy (CRT) and surgery in patients (pts) with stage III non-small cell lung cancer (NSCLC): Is bulky mediastinal nodal disease of prognostic importance
7168 Background: Bulky mediastinal nodal involvement at presentation has been considered a poor prognostic factor in pts with stage III NSCLC. We present long-term follow-up from a phase II trial of accelerated fractionation radiation (AFR), concurrent chemotherapy and surgery, to address this issue. Methods: Between 10/94 and 9/00, 105 pts with surgically proven stage IIIA (N=78) or IIIB (N=27) NSCLC underwent induction treatment consisting of a 96-hour continuous cisplatin infusion (20 mg/m2/day) and a 24-hour infusion of paclitaxel (175 mg/m2) concurrent with AFR (1.5 Gy bid) to a dose of 30 Gy. Surgery was scheduled 4 weeks later, with a second identical course of CRT given 4–6 weeks post-operatively to a total dose of 60–63 Gy. Results: With a median follow-up of 59 (range 35–102) months, the projected Kaplan-Meier (KM) 5-year overall survival is 29%. KM 5-year locoregional and distant control are 85% and 39% respectively. KM 5-year survival was better in clinical stage IIIA vs. IIIB pts (33% vs. 19%, P=0.03); clinical responders to induction vs. non responders (36% vs. 17%, P=0.004); and pathologic responders vs. non-responders (45% vs. 11%, P < 0.001). Pathologic stage after surgery also predicted 5-year survival (stage 0-II: 55%; IIIA: 23%; IIIB - IV: 4%; P < 0.001). Pre-treatment mediastinoscopy identified 20 pts with only microscopic intra-nodal involvement in one or more ipsilateral nodes, and 61 pts with gross macroscopic, but ipsilateral, nodal disease. These two groups did not differ in median or 5-year KM survival (27 vs. 29 months, 45% vs. 27%, P= 0.45). The extent of ipsilateral nodal involvement contributed no prognostic information about survival in a Cox multivariable analysis. Conclusions: Clinical stage IIIA disease, clinical and pathologic response to induction, and a lower pathologic stage are important predictors for survival after this CRT protocol for pts with stage III NSCLC. Bulky ipsilateral mediastinal nodal involvement at diagnosis is of no prognostic importance for survival in these pts and should not be a consideration in treatment planning. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 3116
Does gefitinib aggravate radiation induced respiratory dysfunction?
3116 Background: Significant concern has been expressed about the potential for gefitinib to produce interstitial pneumonitis, particularly in association with pulmonary radiation therapy. This possibility is being assessed in an ongoing study of neoadjuvant chemoradiotherapy and gefitinib for patients with locoregionally advanced esophageal cancer. Methods: Patients on this study are treated with 30 Gy of preoperative radiation (150 cGy bid) and a single concurrent chemotherapy course using 5-fluorouracil (1000 mg/m2/day) and cisplatin (20 mg/m2/day), both given as 4-day continuous infusions beginning on the first day of radiation therapy. Gefitinib, 250 mg daily, is given for 28 days, also beginning on day 1 of radiation therapy. Pre-treatment and post-treatment pulmonary function testing, including spirometry and carbon monoxide diffusion capacity (DLCO), is performed in all patients in preparation for surgical resection, which is scheduled no sooner than two weeks after completing the gefitinib. Results: Thus far, 9 patients have been entered on this study, ranging in age from 38–68 (median 59) years. All patients are men; 8 of 9 patients are white and have an adenocarcinoma. All patients had at least T3N0 disease. The mean pre-treatment FEV1 was 92% predicted (range 50%–133%). After chemoradiotherapy the mean FEV1 was 93% predicted (range 61% - 132%). The mean pre-treatment DLCO was 114% predicted (range 81%–138%) and fell to 102% (range 71%–130%) after treatment. This did not represent a clinically meaningful (>20%) reduction in DLCO (P=0.98). After surgery only one patient experienced any pulmonary complication; a post-operative pneumonia which resolved with antibiotic therapy. Conclusion: Limited experience suggests that this gefitinib containing induction regimen does not contribute to the early development of radiation-induced respiratory dysfunction.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 3116
Does gefitinib aggravate radiation induced respiratory dysfunction?
3116 Background: Significant concern has been expressed about the potential for gefitinib to produce interstitial pneumonitis, particularly in association with pulmonary radiation therapy. This possibility is being assessed in an ongoing study of neoadjuvant chemoradiotherapy and gefitinib for patients with locoregionally advanced esophageal cancer. Methods: Patients on this study are treated with 30 Gy of preoperative radiation (150 cGy bid) and a single concurrent chemotherapy course using 5-fluorouracil (1000 mg/m2/day) and cisplatin (20 mg/m2/day), both given as 4-day continuous infusions beginning on the first day of radiation therapy. Gefitinib, 250 mg daily, is given for 28 days, also beginning on day 1 of radiation therapy. Pre-treatment and post-treatment pulmonary function testing, including spirometry and carbon monoxide diffusion capacity (DLCO), is performed in all patients in preparation for surgical resection, which is scheduled no sooner than two weeks after completing the gefitinib. Results: Thus far, 9 patients have been entered on this study, ranging in age from 38–68 (median 59) years. All patients are men; 8 of 9 patients are white and have an adenocarcinoma. All patients had at least T3N0 disease. The mean pre-treatment FEV1 was 92% predicted (range 50%–133%). After chemoradiotherapy the mean FEV1 was 93% predicted (range 61% - 132%). The mean pre-treatment DLCO was 114% predicted (range 81%–138%) and fell to 102% (range 71%–130%) after treatment. This did not represent a clinically meaningful (>20%) reduction in DLCO (P=0.98). After surgery only one patient experienced any pulmonary complication; a post-operative pneumonia which resolved with antibiotic therapy. Conclusion: Limited experience suggests that this gefitinib containing induction regimen does not contribute to the early development of radiation-induced respiratory dysfunction.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 1557
Validation of the RTOG recursive partitioning analysis (RPA) classification for small cell lung cancer-only brain metastases: A single institution experience
1557 Background: Brain metastases clinical trials have generally excluded small cell lung cancer (SCLC) cases. The RTOG developed 3 prognostic classes for brain metastases using a recursive partitioning analysis (RPA), however only 4% of patients had an SCLC diagnosis. Validation of these RPA classes for SCLC-only is important for rational trial design. Methods: A 20-year retrospective review of 164 SCLC patients with brain metastases treated between 4/1983 and 5/2003 was performed. Patients who underwent surgery as part of their treatment were excluded from this study. This provided 154 patients for analysis. RPA criteria used for class assignment were Karnofsky performance status (KPS), primary tumor status (PD), presence of extracranial system metastases (SD) and age. Results: Median follow-up was 4.7 months (range 0.3–40.3). Median age was 65 (range 42–85). Median KPS was 70 (range 40–100). Median number of lesions was 3 (range1–30) [data on 139 patients]. Number of patients with controlled PD and no SD was: 20 (13%) and with SD: 27 (18%); without controlled PD and no SD: 34 (22%) and with SD: 73 (47%). RPA class distribution was: class I- 8 (5%); class II- 96 (62%); class III- 51 (33%). For the whole patient cohort, median survival was 4.9 months, with 4 (2.6%) alive at analysis. Median survival (in months) by RPA class for SCLC-only is: class I- 8.6; class II- 5.3; class III- 2.5. Original RTOG RPA survival (in months) by class is: class I- 7.1; class II- 4.2; class III- 2.3. Outcomes for SCLC-only brain metastases appear similar to the RTOG database. Conclusions: This analysis suggests that the RPA classes are valid for brain metastases from SCLC and supports the inclusion of SCLC patients in future brain metastases trials. This classification may also serve as a basis for historical comparisons. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 1557
Validation of the RTOG recursive partitioning analysis (RPA) classification for small cell lung cancer-only brain metastases: A single institution experience
1557 Background: Brain metastases clinical trials have generally excluded small cell lung cancer (SCLC) cases. The RTOG developed 3 prognostic classes for brain metastases using a recursive partitioning analysis (RPA), however only 4% of patients had an SCLC diagnosis. Validation of these RPA classes for SCLC-only is important for rational trial design. Methods: A 20-year retrospective review of 164 SCLC patients with brain metastases treated between 4/1983 and 5/2003 was performed. Patients who underwent surgery as part of their treatment were excluded from this study. This provided 154 patients for analysis. RPA criteria used for class assignment were Karnofsky performance status (KPS), primary tumor status (PD), presence of extracranial system metastases (SD) and age. Results: Median follow-up was 4.7 months (range 0.3–40.3). Median age was 65 (range 42–85). Median KPS was 70 (range 40–100). Median number of lesions was 3 (range1–30) [data on 139 patients]. Number of patients with controlled PD and no SD was: 20 (13%) and with SD: 27 (18%); without controlled PD and no SD: 34 (22%) and with SD: 73 (47%). RPA class distribution was: class I- 8 (5%); class II- 96 (62%); class III- 51 (33%). For the whole patient cohort, median survival was 4.9 months, with 4 (2.6%) alive at analysis. Median survival (in months) by RPA class for SCLC-only is: class I- 8.6; class II- 5.3; class III- 2.5. Original RTOG RPA survival (in months) by class is: class I- 7.1; class II- 4.2; class III- 2.3. Outcomes for SCLC-only brain metastases appear similar to the RTOG database. Conclusions: This analysis suggests that the RPA classes are valid for brain metastases from SCLC and supports the inclusion of SCLC patients in future brain metastases trials. This classification may also serve as a basis for historical comparisons. No significant financial relationships to disclose.
- 1 May 1999
- Published by Elsevier in Chest Surgery Clinics of North America
- Vol. 9 (2) , 353-368
TECHNIQUES OF PNEUMONECTOMY: Standard Pneumonectomy
- 1 May 1999
- Published by Elsevier in Chest Surgery Clinics of North America
- Vol. 9 (2) , 353-368
TECHNIQUES OF PNEUMONECTOMY: Standard Pneumonectomy
- 1 March 1999
- Vol. 12 (3) , 251-6
Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma.
Induction chemoradiotherapy before esophagectomy for esophageal carcinoma seems to improve patient survival. Given the toxicity of this regimen, it would be useful to predict those patients likely to benefit. p53 is known to mediate apoptosis in response to DNA damage, but there are few data evaluating the relationship between p53 expression and chemoradiosensitivity in human tissues. We immunohistochemically evaluated p53 protein expression in 95 biopsy specimens from patients with esophageal carcinoma before chemoradiotherapy. p53 expression was correlated to the pathologic response identified in subsequent esophagectomy specimens. p53 immunoreactivity was recorded semiquantitatively using the following scale: neg, < 5%; 1+, 5-25%; 2+, 26-50%; 3+, 51-75%; 4+, > or = 76%. Pathologic response in esophagectomy specimens was categorized as overt residual tumor (ORT), minimal residual tumor, and no residual tumor. Of the 95 patients, 64 had adenocarcinoma, and 31 had squamous cell carcinoma. Of those with adenocarcinoma, 46 (72%) of 64 were positive for p53. Thirty-seven (80%) of 46 p53+ patients had ORT, compared with 4 (22%) of 18 p53- patients (P < .001). There was no correlation between the degree of p53 staining and pathologic response. Of those with squamous cell carcinoma, 13 (42%) of 18 were positive for p53. Three (23%) of 13 p53+ patients had ORT, compared with 4 (22%) of 18 p53- patients (P = .96). Our data indicate that overexpression of p53 protein is associated with decreased responsiveness to induction chemoradiotherapy in patients with esophageal adenocarcinoma but that no such association exists in patients with esophageal squamous cell carcinoma.
- 1 March 1999
- Vol. 12 (3) , 251-6
Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma.
Induction chemoradiotherapy before esophagectomy for esophageal carcinoma seems to improve patient survival. Given the toxicity of this regimen, it would be useful to predict those patients likely to benefit. p53 is known to mediate apoptosis in response to DNA damage, but there are few data evaluating the relationship between p53 expression and chemoradiosensitivity in human tissues. We immunohistochemically evaluated p53 protein expression in 95 biopsy specimens from patients with esophageal carcinoma before chemoradiotherapy. p53 expression was correlated to the pathologic response identified in subsequent esophagectomy specimens. p53 immunoreactivity was recorded semiquantitatively using the following scale: neg, < 5%; 1+, 5-25%; 2+, 26-50%; 3+, 51-75%; 4+, > or = 76%. Pathologic response in esophagectomy specimens was categorized as overt residual tumor (ORT), minimal residual tumor, and no residual tumor. Of the 95 patients, 64 had adenocarcinoma, and 31 had squamous cell carcinoma. Of those with adenocarcinoma, 46 (72%) of 64 were positive for p53. Thirty-seven (80%) of 46 p53+ patients had ORT, compared with 4 (22%) of 18 p53- patients (P < .001). There was no correlation between the degree of p53 staining and pathologic response. Of those with squamous cell carcinoma, 13 (42%) of 18 were positive for p53. Three (23%) of 13 p53+ patients had ORT, compared with 4 (22%) of 18 p53- patients (P = .96). Our data indicate that overexpression of p53 protein is associated with decreased responsiveness to induction chemoradiotherapy in patients with esophageal adenocarcinoma but that no such association exists in patients with esophageal squamous cell carcinoma.